Andere Sprachen Cartesian Therapeutics, Inc.

Aktien

A407YS

US8162123025

RNAC

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:17:14 26.06.2024			% 5 Tage	% 1. Jan.
22,66 ^USD	-5,82 %		-0,22 %	+10,43 %

04.06.	CARTESIAN THERAPEUTICS, INC. : Oppenheimer bekräftigt seine Kaufempfehlung	ZM
24.05.	CARTESIAN THERAPEUTICS, INC. : Mizuho Securities bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cartesian Therapeutics Announces New Employment Inducement Grant	06.06.
Cartesian Gets Regenerative Medicine Advanced Therapy Label for Myasthenia Gravis Drug Candidate	22.05.
Cartesian Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for Descartes-08 for the Treatment of Myasthenia Gravis	22.05.
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis	22.05.
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	13.05.
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	08.05.
Cartesian Therapeutics Announces New Employment Inducement Grants	06.05.
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting	22.04.
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04.04.
Cartesian Therapeutics Announces New Employment Inducement Grants	04.04.
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split	28.03.
Cartesian Therapeutics : Termination of Material Agreement - Form 8-K	14.03.
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	14.03.
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	07.03.
Cartesian Therapeutics to Participate in Upcoming Investor Conferences	06.03.
Cartesian Therapeutics Announces New Employment Inducement Grant	05.03.
Cartesian Therapeutics, Inc. Announces Resignation of Aymeric Sallin as Member of the Board of Director and Member of Compensation Committee	05.03.
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	05.03.
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cartesian Therapeutics, Inc.

Aktien

A407YS

US8162123025

RNAC

Andere Sprachen

Filter